Eban II: Intervention for HIV Sero-Discordant Couples

Recruiting in Palo Alto (17 mi)

+7 other locations

Overseen byGail E Wyatt, PhD

Age: 18 - 65

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: University of California, Los Angeles

No Placebo Group

Trial Summary

What is the purpose of this trial?

This study focuses on the implementation of an evidence-based HIV risk reduction intervention for HIV-serodiscordant, heterosexual African American couples ("Eban II") in two geographic areas (Northern and Southern California - roughly, Alameda and Los Angeles Counties) that have a high prevalence of HIV infection and risk conditions among African Americans. The Specific Aims are as follows: 1. To evaluate implementation of Eban for HIV serodiscordant African American couples in 10 CBOs in California. To do this, we will document the implementation process and identify barriers and facilitators to Eban's adoption and use by the CBOs. We will interview 200 staff at CBOs to obtain this information. 2. To evaluate the effect of Eban on behavioral and biological outcomes among 180 couples, specifically incidents of protected sex, proportion of condom use, and incident sexually transmitted infections. Eban will be assessed using a randomized delayed enrollment (waitlist) control design to evaluate the impact of treatment on outcomes at posttest and 3-month follow-up (i.e., at these 10 CBOs, Eban will be conducted and offered to couples and evaluated for effectiveness - that is, how well it works in the real world.) 3. To determine the cost-effectiveness of implementation of Eban, based on implementation costs and potential cost savings.

Eligibility Criteria

Inclusion Criteria

Must be in a relationship with study partner for at least 3 months

Both partners must be 18 years or older

At least one partner must identify as African American/Black

See 3 more

Treatment Details

Interventions

Risk Reduction (Behavioral Intervention)

Participant Groups

2Treatment groups

Experimental Treatment

Active Control

Group I: Risk ReductionExperimental Treatment1 Intervention

The Risk Reduction group will receive the Eban II Intervention upon enrollment. This group will do the following: * Provide HIV and STI test results * First Interview * Attend 8 sessions - 1 session per week * Second interview occurs immediately following the 8th session with HIV and STI tests * Third interview occurs 3 months after the 8th session with HIV and STI tests

Group II: WaitlistActive Control1 Intervention

The Waitlist group will receive the same intervention after waiting for the Risk Reduction group to complete the entire intervention. * Provide HIV and STI test results * First Interview * No sessions for 8 weeks * Second interview and proof of HIV and STI status occurs after the 8 weeks from when you were enrolled * Third interview occurs 3 months after the 8th session with HIV and STI tests The Waitlist Group will then be invited to participate in the Risk Reduction group activities. * Attend 8 sessions - 1 session per week * Fourth interview occurs immediately after the 8th session with HIV and STI tests * Fifth interview occurs 3 months after the 8th session with HIV and STI tests